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Context: Cushing’s syndrome (CS) is a rare disease of endogenous hypercortisolism
associated with high morbidity and mortality. Diagnosis and classification of CS is still
challenging.
Objective: Circulating microRNAs (miRNAs) are minimally invasive diagnostic markers.
Our aim was to characterize the circulating miRNA profiles of CS patients and to identify
distinct profiles between the two major CS subtypes.
Methods: We included three groups of patients from the German Cushing’s registry:
ACTH-independent CS (Cortisol-Producing-Adenoma; CPA), ACTH-dependent pituitary
CS (Cushing’s Disease; CD), and patients in whom CS had been ruled out (controls).
Profiling of miRNAs was performed by next-generation-sequencing (NGS) in serum
samples of 15 CS patients (each before and after curative surgery) and 10 controls.
Significant miRNAs were first validated by qPCR in the discovery cohort and then in an
independent validation cohort of 20 CS patients and 11 controls.
Results: NGS identified 411 circulating miRNAs. Differential expression of 14 miRNAs were
found in the pre- and postoperative groups. qPCR in the discovery cohort validated 5 of the
significant miRNAs from the preoperative group analyses. Only, miR-182-5p was found to be
significantly upregulated in the CD group of the validation cohort. Comparing all CS samples
as a group with the controls did not reveal any significant differences in expression.
Outcome: In conclusion, our study identified miR-182-5p as a possible biomarker for CD,
which has to be validated in a prospective cohort. Furthermore, our results suggest that
presence or absence of ACTH might be at least as relevant for miRNA expression as
hypercortisolism itself.
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INTRODUCTION
Cushing’s syndrome (CS) is a severe disease resulting from
prolonged exposure to excessively high levels of cortisol (1). In
the majority of patients hypercortisolism is due to ACTH
secretion by corticotroph adenomas of the pituitary gland
resulting in Cushing’s disease (CD) (2). In approximately 20%
of cases cortisol is secreted autonomously by the adrenal cortex.
Adrenal dependent CS is mostly caused by unilateral cortisol-
producing adrenal adenomas (CPA), rare causes are cortisol-
secreting adrenocortical carcinomas (ACC), primary bilateral
macronodular adrenocortical hyperplasia (PBMAH), bilateral
CPAs and primary pigmented micronodular adrenal disease
(PPMAD) (3, 4). Prolonged exposure to cortisol causes visceral
obesity, resistance to insulin, osteoporosis, altered lipid and
glucose metabolism, hypercoagulability, neuropsychiatric
disorders and hypertension (5). The clinical features of CS vary
widely, and no single specific symptom is present in every
patient, making the diagnosis and subtyping of CS difficult and
subject to false-positive and false-negative test results (6).
However, timely and precise diagnosis of CS is crucial to avoid
the high mortality and morbidity of affected patients (7). This
clinical situation calls for more reliable, specific, and selective
biomarkers for diagnosing CS.
MicroRNAs (miRNAs) are short (20–24 nucleotides) non-
coding RNA molecules with diverse cellular regulatory functions
including differentiation, proliferation and apoptosis (8). While
the majority of miRNAs exist intracellularly, a significant
number of miRNAs have been observed in extracellular
compartments including plasma, serum, urine, saliva, semen,
ascites, amniotic pleural effusions, and cerebrospinal fluid (9, 10).
There are two major populations of circulating miRNAs, those
vesicle-associated (which represents 90% of circulating miRNAs)
and those non–vesicle-associated (11). Circulating miRNA
profiles have been found to be very dynamic and abnormal
levels of distinct miRNAs could be observed in specific biological
stages of diseases and particularly during the development,
invasion and metastasis of cancer (12). Circulating miRNAs
fulfil several properties of non-invasive biomarkers, such as
availability in various bodily fluids, sequence conservation
between human and various preclinical models and availability
of sensitive technologies for their quantification (13).
In recent years circulating miRNAs have been investigated
as potential biomarkers for adrenal diseases with a total of eight
studies investigating the pattern of extracellular miRNAs in
adrenocortical tumors to date (14). The miRNAs investigated
were found to aid in different forms of adrenal adenomas (15).
Importantly, circulating miRNAs, miR-34a, and miR-483-5p
were identified as candidate serum biomarkers distinguishing
between benign and malignant adrenocortical tumors (16). In
ectopic ACTH-dependent CS, there has been a single study
reporting differences in plasma miR-expression (17). However,
to the best of our knowledge, studies comparing different types
of CS with each other have not yet been performed. The aim of
this study was to compare circulating miRNA expression
profiles of patients with different forms of CS and controls
and evaluate their applicability as biomarkers. Therefore, we
compared circulating miRNA profiles in serum samples of
patients with CPA and patients with CD with those of
patients in whom CS had been ruled out (controls). In
addition to preoperative serum samples, we have also
analyzed miRNA profiles in paired pre- and post-operative
samples. To investigate possible short-term changes in miRNA
profiles, we also analyzed serum samples after 1 mg low-dose
dexamethasone testing in control patients.
MATERIALS AND METHODS
Patients and Ethics Approval
We conducted a retrospective, bi-centric study, based on a
collection of pre- and post-operative serum samples of patients
with Cushing’s syndrome and controls at the Endocrinology
Unit of the University Hospital of Munich and of the University
Hospital of Würzburg. Diagnosis of CS followed current
guidelines was based on the presence of relevant clinical
features and biochemical confirmation through the following
screening tests: increased 24-hour urinary free cortisol; loss of
diurnal circadian cortisol rhythm with midnight salivary or
serum cortisol concentrations; insufficiently suppressed serum
cortisol levels after overnight administration of 1 mg of
dexamethasone and suppressed plasma ACTH levels (as
shown in Table 1). All patients were registered as part of
ongoing registries and biobanks (ENS@T, European Network
for the Study of Adrenal Tumor; NeoExNet, Exzellenz-
Netzwerkes für neuroendokrine Tumoren Muenchen). The
study was approved by the Ethics Committees of the University
of Munich and Würzburg and written informed consent was
obtained from all enrolled patients. All experiments were
performed according to current guidelines and protocols. The
discovery cohort contained 5 patients with overt adrenal
dependent CS (CPA), 10 patients with overt pituitary dependent
CS scheduled for surgery (CD) and 10 patients who were
submitted in our outpatient clinic with suspicion of CS and in
whom CS was ruled out (controls). Serum of the patients with
CPA and CD was collected at the time of diagnosis preoperatively
and after successful adrenalectomy and transsphenoidal
pituitary surgery, respectively. Therefore, in total 40 serum
samples of the discovery cohort were used for next-generation-
sequencing (NGS): 5 preoperative CPA, 5 postoperative CPA, 10
preoperative CD, 10 postoperative CD, and 10 controls. As a
confirmatory cohort, an independent series of 11 patients with
CPA, 9 patients with CD and 11 controls were analyzed. Of the 11
controls of the confirmatory cohort also serum samples after 1 mg
dexamethasone test were included (Table 1). Age and sex did not
differ significantly between the groups (Table 1). All blood
samples were collected in the morning (08:00–11:00 AM). All of
our patients with CPA and CD, respectively, revealed
postoperative adrenal insufficiency and were in need of a
cortisol replacement therapy. At the timepoint of the
postoperative blood sampling 87% of the patient still received
hydrocortisone between 10 to 25 mg.
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RNA Extraction
Total RNA isolation was carried out from all serum samples
(450 µl) by miRNeasy Serum/Plasma Kit (Qiagen GmbH,
Hilden, Germany) and stored at −80°C until further use.
Sample Processing and miRNA
Expression Profiling from Serum Samples
by Next-Generation Sequencing (NGS)
RNA integrity and absence of DNA was confirmed by
Bioanalyzer RNA Nano chips (Agilent Technologies, St. Louis,
MO) and Qubit DNA High sensitivity kit, respectively.
Sequencing libraries were prepared using the Illumina TruSeq
Small RNA Library Preparation Kit. Next generation sequencing
was performed on 2 lanes of an Illumina HiSeq2500 (Illumina,
San Diego, CA) multiplexing all samples (single end read, 50 bp).
The quality of sequencing reads was verified using FastQC0.11.5
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc)
before and after trimming. Adapters were trimmed using
cutadapt (18). Reads with <15 bp and >40 bp insert sequences
were discarded. Alignment of reads was performed using
miRBase V21 (19) with sRNAbench (20). For normalization
and identification of differentially expressed miRNAs EdgeR and
DeSeq in R was used (21–23). miRNAs with an at least 5 raw
count per library were included. Disease groups were compared
using the unpaired Mann–Whitney test, and, to decrease the
false discovery rate, a corrected p-value was calculated using the
Benjamini–Hochberg method. Adjusted p < 0.05 and log2 fold of
change >1.5 were the cut-off for significance. The RNA seq data
generated in this study have been submitted to the NCBI GEO
with accession number GSE156693.
Validation of Individual miRNAs
Significantly differentially expressed miRNAs found by NGS were
validated by RT-qPCR. Reverse transcription of RNA was
performed using the TaqMan MicroRNA Reverse Transcription
Kit (Thermo Fisher Scientific). As reference miRNA, hsa-miR-16-
5p was used (12, 24, 25). Quantitative real-time PCR was performed
using the TaqMan Fast Universal PCR Master Mix (2x) (CN:
4352042; Thermo Fisher Scientific) on a Quantstudio 7 Flex
Real-Time PCR System (Thermo Fisher Scientific) in accordance
with the manufacturer’s protocol for TaqMan Advanced miRNA
assays (CN: A25576; Thermo Fisher Scientific). The miRNAs along
with their respective TaqMan assay IDs are given in Table S1 (26).
Contamination controls contained no cDNA templates.
Statistical Analysis and Software
R version 3.6.1 was used for statistical analyses. To identify miRNAs
differentially expressed, generalized linear model (GLM, a flexible
generalization of ordinary linear regression that allows for variables
that have distribution patterns other than a normal distribution) in
the software package edgeR (Empirical Analysis of DGE in R) was
employed to calculate p-values (25, 27). p-values were adjusted
using the Benjamini–Hochberg false discovery rate (FDR)
procedure (27). GraphPad Prism Version 8 was used for
statistical analysis of qPCR results. To quantify the miRNAs in
qPCR, the dCt method [delta Ct (cycle threshold) value equals
target miRNA’s Ct minus housekeeping miRNA’s Ct was used
(Excel 2016, Microsoft, Redmond, WA, USA). The ANOVA test
with Bonferroni correction for three groups and Mann-Whitney
test for two groups (CS vs Controls) were used for differentially
expressed comparisons (28, 29). Receiver operating characteristic
(ROC) analysis was performed on miRNAs that could have




NGS was performed in the discovery cohort of 5 CPA (before
and after curative surgery), 10 CD (before and after curative
surgery), and 10 control serum samples (total n= 40) and
detected a total of 411 miRNAs. No significant influence of
batch preparation, age, and sex on the miRNA expression profile
was found [Figure S1 (26)]. Differential analysis was performed
between the groups (CPA, CD, and controls) to identify any
characteristic miRNA profile associated with one of the entities
before and after surgery, respectively. No significant changes















































































































Data are given as median with 25th and 75th percentile in brackets.
CPA, cortisol producing adenoma; CD, Cushing’s disease; BMI, body mass index.
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were observed based on the comparison of all CS samples pooled
together versus control samples (Figure 1A). Differential
expression levels in three miRNAs, namely miR-185-5p, miR-
146b-5p, and miR-342-3p were found when comparing CPA
samples with controls (Figure 1B), while only miR-182-5p was
found to be significantly regulated between CD samples and
controls (Figure 1C). Post-hoc analyses between CPA and CD
revealed that the most pronounced differences included 6
miRNAs: miR-96-5p, miR-146b-5p, miR-183-5p, miR-185-5p,
miR-616-5p, and miR-629-5p (Figure 1D). Sequencing of the
postoperative samples showed significantly different expression
of four miRNAs (miR-429, miR-141-3p, miR-215-5p, miR-200a-
3p) between CPA and controls [Figure S2B (26)]. No significant
differences were observed while comparing all postoperative CS
samples pooled together with control samples [Figure S2A (26)],
the postoperative CD samples with controls [Figure S2C (26)]
and the postoperative CPA serum samples vs CD postoperative
samples [Figure S2D (26)]. Analysis of the preoperative samples
revealed no major difference in the distribution of the top 20
abundant genes compared to the controls [Figure S3 (26)].
Validation of Selected miRNAs by qPCR
NGS identified 8 miRNAs that were significantly dysregulated in
the preoperative group and 4 miRNAs that were significantly
altered in the postoperative group (see Table 2). qPCR analysis
of these miRNAs revealed significant differences in 5 out of the 8
preoperative miRNAs (miR-185-5p, miR-183-5p, miR-182-5p,
miR-146b-5p, and miR-96-5p), but in none of the postoperative
cohort samples [Figure S4 (26)]. To further validate the results
from the discovery cohort, we assessed the remaining five
significant miRNAs in an independent set of samples (CPA,
n=11; CD, n=9 controls, n=11). Only miR-182-5p was confirmed
to be significantly upregulated in the preoperative group of the
independent cohort (Figure 2B). The diagnostic utility of miR-
182-5p was evaluated using a ROC analysis (Figure 3). For CD
samples from both discovery and validation cohorts, the area
under curve (AUC) was 0.87, (95% confidence interval: 0.7 to 1.0,
P = 0.0003), while for the CS samples pooled together the area
under curve (AUC) was 0.84 (95% confidence interval:0.7 to 0.9,
P = 0.0002). The AUC was further lower for CPA samples, 0.8
(95% confidence interval:0.5 to 0.9, P = 0.003). Further,
correlation analyses of the gene expression levels with clinical
parameters revealed no significant results (Table S2). As none of
the postoperative miRNAs were found to be significantly
different in the discovery cohort, they were not further
analyzed in the validation cohort. Finally, to investigate
whether the five selected circulating miRNAs are affected by
short-term exogenous glucocorticoids, we analyzed the
TABLE 2 | Comparison of results of RNA Sequencing and qPCR in selected miRNAs.
RNA sequencing qPCR
Gene symbol Mean Count Position CPA vs Controls CD vs Controls CPA vs CD CPA vs Controls CD vs Controls CPA vs CD
miR-96-5p 689 122 1.31 −1.77 −3.08*** −0.22 1.77* −1.99*
miR-146b-5p 842 114 2.03* −0.16 −2.18** −0.38 2.57** −2.95*
miR-182-5p 5,493 46 −0.58 −1.62*** −1.03 0.75 1.73* −0.98
miR-183-5p 885 112 0.81 −1.43 −2.23** 0.07 2.20* −2.14
miR-185-5p 40 313 4.43 −0.31 −4.74*** 0.54 1.78* −1.24
miR-342-3p 1,024 105 1.64 −0.10 −1.75* 0.47 0.31 0.16
miR-616-5p 31 337 0.83 −0.32 −1.15* 0.59 0.99 −0.40
miR-629-5p 37 318 1.59 −0.33 −1.92* −0.15 −1.02 0.87
*P < 0.05, **P < 0.01, and ***P < 0.001. Gene expression is represented as log2fold change. CPA, cortisol producing adenoma; CD, Cushing’s disease. The potential biomarker candidate
has been highlighted in bold.
A B DC
FIGURE 1 | Differentially expressed miRNAs from NGS of preoperative group. Volcano plot showing the relationship between fold change (log2foldchange) and statistical
significance (−log10pvalue). The red points in the plot represent the differentially expressed miRNAs with FDR <0.05 considered as statistically significant. CPA, cortisol
producing adenoma; CD, Cushing’s Disease, CS, Cushing syndrome represents CPA and CD, taken together. Volcano plot showing the relationship between fold change
(log2foldchange) and statistical significance (-log10pvalue) for the groups CS vs Controls (A), CPA vs. Controls (B), CD vs. Controls (C), CPA vs CD (D).
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expression levels of the miRNAs in serum samples before and
after 1 mg of dexamethasone was given 9 h before the control
patients of the independent cohort. miR-185-5p and miR-96-5p
expression was found to be significantly modulated by
dexamethasone treatment (Figure 4).
DISCUSSION
Diagnosis of CS is still challenging due to the broad
symptomatology and the clinical overlap with metabolic
syndrome (30). Upon CS diagnosis, treatment is complicated
by difficulties in distinguishing between the different subtypes of
CS. Of the CS subtypes, CD is the dominant form and a variety of
dynamic tests and robust imaging procedures are necessary for
diagnosis (5). Unsuspected pituitary and adrenal incidentalomas
are increasingly foundwith the widespread use of abdominal and
cranial imaging (31). For pituitary incidentaloma the rate ranges
between 3.7% and 37% (32). Therefore, we hypothesized that a
potential miRNA based diagnostic should aid in the diagnosis of
CS or its subtypes as circulating miRNAs have proven their
potential as minimal invasive biomarkers in other diseases
(33). Few studies have investigated circulating miRNA profiles
in CS, and appropriate controls matched for sex, BMI and
comorbidities were missing (17, 34). Therefore, in our study
we included clinically relevant control samples to identify a
unique circulating miRNA signature associated with CS. The
control group consisted of patients submitted with the suspicion
of CS in the outpatient clinic but in whom CS was ruled out by
several diagnostic tests and follow-up. We decided deliberately
for such a control group, as this reflects clinical practice and a
new biomarker would have to demonstrate relevance in this
clinical scenario. In addition, to ensure technical consistency
across the various biological samples, the RNA from different
groups, including controls, were isolated in batches and possible
batch preparation effect was also analyzed in the NGS data. As
can be seen [Figure S1 (26)], no major changes were found,
indicating the changes observed in the NGS data, likely arises
from inherent biological differences and not due to batch effect.
The sequencing datawere also found to not be influenced by both
age and sex [Figure S1 (26)].Only miR-182-5p was confirmed as
differentially expressed by qPCR of the discovery and the
validation cohorts. ROC analysis for the diagnostic power of
miR-182-5p resulted in an AUC of 0.89 in separating CD
patients from controls, and an AUC of 0.85 in differentiating
all patients with CS from controls. This suggests that circulating
miR-182-5p may function as a biomarker specifically for CD.
Our observation draws strength from related studies wherein
circulating miR-182-5p has been successfully identified as a
diagnostic biomarker in colorectal adenocarcinoma (35) and
coronary artery disease (36). Furthermore, the overexpression of
miR-182-5p in prolactin-secreting pituitary adenomas tissues
has also been documented (37). However, the potential use of
circulating miR-182-5p as a biomarker in CD should be seen
with caution due to the differences observed between NGS and
qPCR. While miR-182-5p was found to be significantly
downregulated in CD in comparison to controls by NGS
(Table 2), qPCR in discovery and validation cohorts revealed
significant upregulation of CD in comparison to controls (Table
2 and Figure 2). This difference could be possibly explained by
the high sensitivity observed with qPCR in comparison to the
high throughput genomic profiling technologies including NGS
and microarray (38). Concurrently, studies with a wholesome
approach to circulating miRNAs, namely through microarray
and NGS, are often not able to validate their sequencing and
array results (25, 34). miR-182-5p along with miR-96-5p and
miR-183-5p, were also found to be deregulated in CPA and CD
samples compared to the controls (Figures 1B, C). Altogether
these miRNas belong to the miR-183 cluster. This miR-183
cluster is known to play a role in a variety of non-sensory
diseases, including cancer and neurological, psychiatric and
auto-immune disorders (39). Furthermore, the expression
profiles of the miR-183 cluster was found to be altered in
adrenal tissues of patients with pheochromocytoma (40).
A
B
FIGURE 2 | Results of qPCR of the significant miRNAs of preoperative
group. Data are represented as Mean ± Standard deviation (SD) of -dCT
values. (A) Expression analysis in discovery cohort selected for validation from
NGS. (B) Expression analysis in validation cohort of the significant miRNAs
from discovery cohort. Statistics: ANOVA test with Bonferroni correction to
detect significant differences between patient groups with at least a
signification of p-value < 0.05. *P < 0.05 and **P < 0.01.
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Surprisingly, NGS did not identify any distinct miRNA
expression pattern between CS taken as a single group and the
control group (Figure 1A). ACTH itself might lead to changes in
the circulating miRNA profile that are more relevant as the
hypercortisolism which is present in both forms of CS. The
modulation of miRNAs by ACTH has been characterized in mice
(41) but distinct studies of ACTH modulation on circulating
miRNAs are missing. We speculate that the similarity in
phenotype between CS and this specific control group might
have contributed to this observation, too. Additionally, including
only patients with benign tumors might have led to the discovery
of a low amount of changes in circulating miRNA profiles as cell
disruption and release of miRNAs from tumour cells into the
blood, typical features of malignant neoplasms, are minimal.
The CPA samples show a far more diverging pattern for their
qPCR expression patterns in both the validation and discovery
cohort. While only miRNA-146b and miRNA-96-5p were found
to be significantly altered between CPA and controls of the
discovery cohort, similar differential expression was not observed
in the CPA of the validation cohort. The discrepancy might be
explained by possible heterogeneity in CPA samples, speculated
from previous adenoma studies (34). Decmann et al. recently
reported heterogeneity associated with complex underlying
pathology to be the possible reason for the observed
discordance between NGS and qPCR of adenoma samples.
Finally, we also investigated the influence of short-term
regulation of the pituitary-adrenal-axis on circulating miRNAs.
For this analysis we focused on the 5 selected miRNAs miR-96-
5p, miR-146b-5p, miR-182-5p, miR-183-5p, and miR-185-5p. Of
the five selected miRNAs, miR-96-5p was significantly
upregulated and miR-185-5p was significantly downregulated
in post dexamethasone samples. Hormonal regulation of adrenal
related miRNAs has been established in two murine in vivo
studies for miR-96-5p (41, 42). For miR-185-5p, in vitro evidence
of the influence of dexamethasone exist through the observed
downregulation of the gene miR-185-5p during ameloblast
differentiation under the influence of dexamethasone treatment
(43). Therefore, it is tempting to speculate that the changes
observed in the post dexamethasone samples could be a hint of
possible hormonal regulation on the expression of these genes.
Thusly, this influence needs to be taken into account in case of
possible future application of the miRNAs in diagnostic setting
involving dexamethasone.
The origin of circulating miRNAs is still subject to
speculation. Since CS is not a malignant disease there is no
concrete proof that the miRNAs significantly altered in the
circulation are the result of specific tissue dysfunctions.
Therefore, the study was limited only to identify and
characterize circulating miRNA changes. Concurrently, there
have been similar reports of increased miR182-5p expression
in prolactin pituitary tumors (37) and ACTH induced up-
regulation of miRNA-182-5p in murine adrenal glands. For a
comprehensive mechanistic understanding behind 182-5p in CD
in depth tissue based molecular analyses is required which is
beyond the scope of the current paper (42).
A B C
FIGURE 3 | Evaluation of the diagnostic applicability of miR-182-5p by receiver operating characteristic (ROC) curves. ROC curves were plotted for CS (represents
CPA and CD) vs controls (A), CD vs. controls (B) and CPA vs. controls (C) from the discovery and validation cohort. CPA, cortisol producing adenoma; CD,
Cushing’s Disease, CS, Cushing syndrome represents CPA and CD, taken together.
FIGURE 4 | Results of qPCR analysis of 1 mg dexamethasone test on
circulating miRNA. Data are represented as Mean ± Standard deviation (SD)
of -dCT values Statistics: ANOVA test with Bonferroni correction to detect
significant differences between patient groups with at least a signification of p
value <0.05. *P<0.05 and **P<0.01.
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In conclusion, we report distinct miRNA expression profiles
associated with CD and CPA through NGS and qPCR
confirmed miR-182-5p as the isolated miRNA to be
differentially regulated. The identification of only one miRNA
as a potential biomarker is speculated to be because of the
following reasons: (1) We worked with 3 groups (CPA vs. CD
vs. controls), and did an overall analysis and then post-hoc
analysis. In this constellation it is more difficult to get
significant results. (2) The number of patients per group was
relatively low. (3) The controls were not healthy, but showed
some similar clinical features as patients with Cushing’s
syndrome. (4) As CPA and CD is a benign disease, there is
no cell rupture and therefore, no release of miRNAs in the
circulation. Technical and biological variations observed in the
study warrants analysis using larger cohorts and more
robust clinically relevant controls before considering miR-
182-5p as a biomarker. Furthermore, our results suggest that
presence or absence of ACTH might be at least as relevant for
hypercortisolism per se.
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